Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.
about
Reverse phase protein microarrays advance to use in clinical trialsMass spectrometry-based characterization of the vitreous phosphoproteomeAqueous cytokine and growth factor levels do not reliably reflect those levels found in the vitreous.Sequential in-office vitreous aspirates demonstrate vitreous matrix metalloproteinase 9 levels correlate with the amount of subretinal fluid in eyes with wet age-related macular degeneration.Reverse phase protein arrays: mapping the path towards personalized medicine.Molecular biomarkers in glaucomaProteomic analysis of vitreous biopsy techniquesRetinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress.Emerging therapeutic approaches in the management of retinal angiogenesis and edema.Trends in proteomic analysis of human vitreous humor samples.Translational vitreous proteomics.Reverse Phase Protein Microarrays.Principles of Ocular Pharmacology.The potential impact of recent insights into proteomic changes associated with glaucoma.Effects of timing of vitrectomy performed for open-globe injury patients on the thickness of retinal nerve fiber layer.Safety and Feasibility of Quantitative Multiplexed Cytokine Analysis From Office-Based Vitreous Aspiration.Clinical pharmacology of intravitreal anti-VEGF drugs.
P2860
Q28384553-DD012652-63A9-420D-A1A7-F4C068036C59Q34665212-F9ACD551-FA8E-42BF-988E-A0E5125DB621Q35575062-E207C88A-1D4B-4897-A02F-D5712B113D8AQ36073882-FB7B1B41-EF25-46DE-BFE6-F1C86452B98AQ36519831-044B4318-3191-46DC-8E09-5C60CB8C0705Q36530573-733D1352-61E7-424A-AF4A-DB0F0F28B25BQ36797319-958BF3DB-DFF8-4E35-82C0-4D48E2C3D18EQ37055774-91086C0B-CECD-4C14-B5ED-42D5E5F25ED8Q37822290-57EC5CAF-6206-45FC-BE12-392FB45FDFFCQ38211623-1030018F-8992-48D6-900C-8AEB790864D9Q38454698-296DD903-21C2-4AF2-AADE-B4791E43080BQ38787411-D9467AD0-B5F9-4578-9211-358938F1F9A1Q38812551-5ADD462C-3EDE-44BA-943B-494F5036608DQ39167734-ECF30FDC-B6C2-4C8D-B6BB-D71D69FC4B13Q39259221-48039CA6-1E76-4D8A-BD6D-9BD080AAC10DQ41891788-22F74031-9D24-4CCA-A008-54C536D8AC29Q48109878-EFF84134-8EFB-4808-86AC-96853E842A6D
P2860
Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activated VEGF receptor shed i ...... iming and monitoring response.
@en
Activated VEGF receptor shed i ...... iming and monitoring response.
@nl
type
label
Activated VEGF receptor shed i ...... iming and monitoring response.
@en
Activated VEGF receptor shed i ...... iming and monitoring response.
@nl
prefLabel
Activated VEGF receptor shed i ...... iming and monitoring response.
@en
Activated VEGF receptor shed i ...... iming and monitoring response.
@nl
P2093
P2860
P1433
P1476
Activated VEGF receptor shed i ...... iming and monitoring response.
@en
P2093
Bert M Glaser
Emanuel F Petricoin
Geetanjali Davuluri
Jianghong Deng
Lance A Liotta
P2860
P304
P356
10.1001/ARCHOPHTHALMOL.2009.88
P407
P577
2009-05-01T00:00:00Z